Angiogenic activity of hepatitis B and C viruses

Antiviral Chemistry and Chemotherapy

Volumn 22, Issue 4, 2012, Pages 159-170

  Vrancken, Kristof ^a   Paeshuyse, Jan ^a   Liekens, Sandra ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AXITINIB; BEVACIZUMAB; BRIVANIB; CEDIRANIB; CELECOXIB; CHLOROTRIANISENE; EPIRUBICIN; ERLOTINIB; ETODOLAC; FORETINIB; LINIFANIB; ORANTINIB; PAZOPANIB; PROPRANOLOL; RAMUCIRUMAB; SORAFENIB; TREBANANIB; UNCLASSIFIED DRUG; VT 122;

ANGIOGENESIS; CANCER RISK; DISEASE COURSE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; VIRUS REPLICATION; BIOLOGICAL MODEL; GENETICS; LIVER TUMOR; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION; VIROLOGY;

CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MODELS, BIOLOGICAL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84860644762     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1987     Document Type: Review

References (95)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-156.
2. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8-29.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48:6-29.
4. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9:191-211.
5. Larson A. The epidemiology of hepatocellular carcinoma in HCV. Curr Hepat Rep 2005; 4:145-152.
6. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
7. Davis GL, Alter MJ, El-Serag H, Poynard T, Jennings LW. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521.e6.
8. Brechot C, Kremsdorf D, Soussan P, et al. Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC): molecular mechanisms and novel paradigms. Pathol Biol (Paris) 2010; 58:278-287.
9. Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol 2005; 42:760-777.
10. Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol 2011; 46:974-990.
11. Chisari F V. Rous-Whipple Award Lecture. Viruses, immunity, and cancer: lessons from hepatitis B. Am J Pathol 2000; 156:1117-1132.
12. Lerat H, Honda M, Beard MR, et al. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. Gastroenterology 2002; 122:352-365.
13. McGivern DR, Lemon SM. Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol 2009; 4:399-415.
14. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001; 234:63-70.
15. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35:421-430.
16. Zhu AX, Duda DG, Sahani DV, Jain RK. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011; 8:292-301.
17. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473:298-307.
18. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438:967-974.
19. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6:273-286.
20. Liekens S, De CE, Neyts J. Angiogenesis: regulators and clinical applications. Biochem Pharmacol 2001; 61:253-270.
21. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.
22. Chun TH, Sabeh F, Ota I, et al. MT1-MMP-dependent neovessel formation within the confines of the three-dimensional extra cellular matrix. J Cell Biol 2004; 167:757-767.
23. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007; 13:74-81.
24. Zhang J, Niu D, Sui J, Ching CB, Chen WN. Protein profile in hepatitis B virus replicating rat primary hepatocytes and HepG2 cells by iTRAQ-coupled 2-D LC-MS/MS analysis: insights on liver angiogenesis. Proteomics 2009; 9:2836-2845.
25. Zhang X, Zhang H, Ye L. Effects of hepatitis B virus X protein on the development of liver cancer. J Lab Clin Med 2006; 147:58-66.
26. Murakami S. Hepatitis B virus X protein: a multifunctional viral regulator. J Gastroenterol 2001; 36:651-660.
27. Koike K, Moriya K, Iino S, et al. High-level expression of hepatitis B virus HBx gene and hepatocarcinogenesis in transgenic mice. Hepatology 1994; 19:810-819.
28. Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol 2005; 15:378-386.
29. Lee SW, Lee YM, Bae SK, Murakami S, Yun Y, Kim KW. Human hepatitis B virus X protein is a possible mediator of hypoxia-induced angiogenesis in hepatocarcinogenesis. Biochem Biophys Res Commun 2000; 268:456-461.
30. Yun C, Lee JH, Wang JH, et al. Expression of hepatitis B virus X (HBx) gene is up-regulated by adriamycin at the post-transcriptional level. Biochem Biophys Res Commun 2002; 296:1157-1163.
31. Moon EJ, Jeong CH, Jeong JW, et al. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J 2004; 18:382-384.
32. Yo o YG, Oh SH, Park ES, et al. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway. J Biol Chem 2003; 278:39076-39084.
33. Yoo YG, Cho S, Park S, Lee MO. The carboxy-terminus of the hepatitis B virus X protein is necessary and sufficient for the activation of hypoxia-inducible factor-1alpha. FEBS Lett 2004; 577:121-126.
34. Park YN, Kim YB, Yang KM, Park C. Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multi step hepatocarcinogenesis. Arch Pathol Lab Med 2000; 124:1061-1065.
35. Dai CX, Gao Q, Qiu SJ, et al. Hypoxia-inducible factor-1 alpha, in association with inflammation, angiogenesis and MYC, is a critical prognostic factor in patients with HCC after surgery. BMC Cancer 2009; 9:418.
36. Liu KG, Hao HY, Zhao H, Niu CY, Li L. Correlation between HBx and VEGF expressions and angiogenesis and metastasis in HBV related hepatocellular carcinoma tissue. Journal of Jilin University (Medicine Edition) 2010; 36:372-375.
37. Sanz-Cameno P, Martin-Vilchez S, Lara-Pezzi E, et al. Hepatitis B virus promotes angiopoietin-2 expression in liver tissue: role of HBV x protein. Am J Pathol 2006; 169:1215-1222.
38. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10:165-177.
39. Thurston G, Rudge JS, Ioffe E, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med 2000; 6:460-463.
40. Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407:242-248.
41. Lobov IB, Brooks PC, Lang RA. Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A 2002; 99:11205-11210.
42. Chen ZB, Shen SQ, Ding YM, et al. The angiogenic and prognostic implications of VEGF, Ang-1, Ang-2, and MMP-9 for hepatocellular carcinoma with background of hepatitis B virus. Med Oncol 2009; 26:365-371.
43. Kessenbrock K, Plaks V, Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 2010; 141:52-67.
44. Lara-Pezzi E, Gomez-Gaviro MV, Galvez BG, et al. The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 2002; 110:1831-1838.
45. Ou DP, Tao YM, Tang FQ, Yang LY. The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by up regulation of matrix metalloproteinases. Int J Cancer 2007; 120:1208-1214.
46. Liu LP, Liang H F, Chen XP, et al. The role of NF-kappaB in Hepatitis b virus X protein-mediated up regulation of VEGF and MMPs. Cancer Invest 2010; 28:443-451.
47. Yu FL, Liu HJ, Lee JW, Liao MH, Shih WL. Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J Hepatol 2005; 42:520-527.
48. Chung TW, Lee YC, Kim CH. Hepatitis B viral HBx induces matrix metalloproteinase-9 gene expression through activation of ERK and PI-3K/AKT pathways: involvement of invasive potential. FASEB J 2004; 18:1123-1125.
49. Kim JR, Kim CH. Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. Int J Biochem Cell Biol 2004; 36:2293-2306.
50. Cheng AS, Chan HL, Leung WK, et al. Expression of HBx and COX-2 in chronic hepatitis B, cirrhosis and hepatocellular carcinoma: implication of HBx in upregulation of COX-2. Mod Pathol 2004; 17:1169-1179.
51. Mazzanti R, Messerini L, Monsacchi L, et al. Chronic viral hepatitis induced by hepatitis C but not hepatitis B virus infection correlates with increased liver angiogenesis. Hepatology 1997; 25:229-234.
52. Messerini L, Novelli L, Comin CE. Microvessel density and clinicopathological characteristics in hepatitis C virus and hepatitis B virus related hepatocellular carcinoma. J Clin Pathol 2004; 57:867-871.
53. Ohmori S, Shiraki K, Sugimoto K, et al. High expression of CD34-positive sinusoidal endothelial cells is a risk factor for hepatocellular carcinoma in patients with HCV-associated chronic liver diseases. Hum Pathol 2001; 32:1363-1370.
54. Salcedo Mora X, Sanz-Cameno P, Medina J, et al. Association between angiogenesis soluble factors and disease progression markers in chronic hepatitis C patients. Rev Esp Enferm Dig 2005; 97:699-706.
55. Kukla M, Zwirska-Korczala K, Gabriel A, et al. sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. Therap Adv Gastroenterol 2009; 2:79-90.
56. Gabriel A, Kukla M, Wilk M, Liszka L, Petelenz M, Musialik J. Angiogenesis in chronic hepatitis C is associated with inflammatory activity grade and fibrosis stage. Pathol Res Pract 2009; 205:758-764.
57. Salcedo X, Medina J, Sanz-Cameno P, et al. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42:696-701.
58. Nasimuzzaman M, Waris G, Mikolon D, Stupack DG, Siddiqui A. Hepatitis C virus stabilizes hypoxia-inducible factor 1alpha and stimulates the synthesis of vascular endothelial growth factor. J Virol 2007; 81:10249-10257.
59. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci U S A 2001; 98:9599-9604.
60. Hassan M, Selimovic D, Ghozlan H, Abdel-kader O. Hepatitis C virus core protein triggers hepatic angiogenesis by a mechanism including multiple pathways. Hepatology 2009; 49:1469-1482.
61. Jahan S, Khaliq S, Ijaz B, Ahmad W, Hassan S. Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis. Virol J 2011; 8:155.
62. Li Y, Chen J, Wu C, Wang L, Lu M, Chen X. Hepatitis B virus/hepatitis C virus upregulate angiopoietin-2 expression through mitogen-activated protein kinase pathway. Hepatol Res 2010; 40:1022-1033.
63. Shin JY, Hur W, Wang JS, et al. HCV core protein promotes liver fibrogenesis via up-regulation of CTGF with TGF-beta1. Exp Mol Med 2005; 37:138-145.
64. Mazzocca A, Sciammetta SC, Carloni V, et al. Binding of hepatitis C virus envelope protein E2 to CD81 up-regulates matrix metalloproteinase-2 in human hepatic stellate cells. J Biol Chem 2005; 280:11329-11339.
65. Núñez O, Fernandez-Martinez A, Majano PL, et al. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 2004; 53:1665-1672.
66. Waris G, Siddiqui A. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J Virol 2005; 79:9725-9734.
67. Schmitt M, Horbach A, Kubitz R, Frilling A, Haussinger D. Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion. J Hepatol 2004; 41:274-283.
68. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic infammatory liver disease. Hepatology 2004; 39:1185-1195.
69. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72:1605-1621.
70. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
71. Fiedler U, Reiss Y, Scharpfenecker M, et al. Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med 2006; 12:235-239.
72. Schweighofer B, Testori J, Sturtzel C, et al. The VEGF-induced transcriptional response comprises gene clusters at the crossroad of angiogenesis and inflammation. Thromb Haemost 2009; 102:544-554.
73. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-1186.
74. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fuorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
75. Greten TF, Korangy F, Manns MP, Malek NP. Molecular therapy for the treatment of hepatocellular carcinoma. Br J Cancer 2009; 100:19-23.
76. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
77. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
78. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008; 26:2992-2998.
79. Malka D, Dromain C, Farace F, et al. Bevacizumab in patients (pts) with advanced hepatocellular carcinoma (HCC): preliminary results of a Phase II study with circulating endothelial cell (CEC) monitoring. J Clin Oncol 2007; 25 Suppl 18:4570.
80. Louaf S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): results of a Phase II study. Cancer 2007; 109:1384-1390.
81. Cheng A. Phase III trial of sunitinib (Su) versus sorafenib (So) in advanced hepatocellular carcinoma (HCC). 47th Annual Meeting of the American Society of Clinical Oncology (ASCO). 3 June 2011, Chicago, IL, USA. Abstract 4000.
82. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8:592-603.
83. Bae SH, Jung ES, Park YM, et al. Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398. Clin Cancer Res 2001; 7:1410-1418.
84. Shiota G, Okubo M, Noumi T, et al. Cyclooxygenase-2 expression in hepatocellular carcinoma. Hepatogastroenterology 1999; 46:407-412.
85. Kondo M, Yamamoto H, Nagano H, et al. Increased expression of COX-2 in nontumor liver tissue is associated with shorter disease-free survival in patients with hepatocellular carcinoma. Clin Cancer Res 1999; 5:4005-4012.
86. Bassiouny AR, Zaky A, Neenaa HM. Synergistic effect of celecoxib on 5-fuorouracil-induced apoptosis in hepatocellular carcinoma patients. Ann Hepatol 2010; 9:410-418.
87. Wada H, Nagano H, Yamamoto H, et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 2006; 26:414-423.
88. Liu F, Wang P, Jiang X, et al. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008; 99:2055-2061.
89. Huang H, Bhat A, Woodnutt G, Lappe R. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer 2010; 10:575-585.
90. Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res 2010; 70:2213-2223.
91. Malka D, Pacault V, de Baere T, Ducreux M, Boige V. Antitumoral effect of celecoxib in hepatocellular carcinoma. J Clin Oncol 2005; 23:4805-4806.
92. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomized, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10:25-34.
93. Yau T, Chen PJ, Chan P, et al. Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. Clin Cancer Res 2011; 17:6914-6923.
94. Kanai F, Yoshida H, Tateishi R, et al. A Phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2011; 67:315-324.
95. Bartenschlager R, Cosset FL, Lohmann V. Hepatitis C virus replication cycle. J Hepatol 2010; 53:583-585.